PDS Biotechnology Corp (PDSB)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.30-7.80%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · PDSB
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
PDSB — CEO transition
Dated 2026-10-20
Director: The simultaneous resignation of four directors (including the majority of the board) and immediate replacement is a significant governance event, but it is not a departure of a senior executive officer like a CEO or CFO.
Why it matters: PDS Biotech plans to seek outside funding for PDS0101. A deal could support more study work without relying only on company cash.
Supportive ifA company filing or release names a PDS0101 partner or outside funding deal with stated terms.
Worry ifThe next two quarterly updates report no partner or outside funding, or say PDS0101 work remains paused.
Why it matters: These results cover studies in prostate, colorectal, and Kaposi sarcoma. Positive results could support the lead program in more than one cancer group.
Watch forAt least one readout by Q2 2028 reports its stated study results on time and meets its main goal.
Also watch forA planned readout slips past Q2 2028, or a reported study fails its main goal.
Why it matters: A clear Phase 3 plan would show how PDS0301 moves beyond the Phase 2 study. A delay or weaker design could slow that path.
Watch forThe company names the Phase 3 design, patient group, control arm, and start date for PDS0301 in mCRC.
Also watch forThe company reports no Phase 3 plan by its next two quarterly updates, or says the trial is delayed.
Why it matters: Cash fell to $5.6 million at June 30, and the September placement brought in $11.3 million gross. Runway and new funding terms matter for trial plans.
Worry ifThe November 12 update gives a longer cash runway than the prior report and confirms funds for the planned PDS0301 work.
Less concerning ifThe update gives a shorter runway, announces another share sale, or delays PDS0301 trial work for lack of funds.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$404 on $10,000 · ±4.0% | How much price usually moves either way. |
| Bad day | $1,219 loss on $10,000 · 12.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,597 loss on $10,000 · 86.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The Phase 2 study reported about 80% survival at 24 months. Later follow-up can test whether that result lasts.
Watch forAn updated report shows 24-month survival at or above about 80% in the same Phase 2 mCRC group.
Also watch forA new report shows 24-month survival below about 80%. Or it says more follow-up cannot confirm the data.
Why it matters: Three new directors joined after four left. Their stated roles include drug development and deal work, so trial steps and a PDS0101 deal are clear tests.
Watch forThe company reports a defined PDS0301 Phase 3 plan or names a PDS0101 partner after the board changes.
Also watch forThe company reports more director departures and a delayed Phase 3 plan. It reports no PDS0101 partner in its next two updates.